Mahon, François-Xavier

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Deininger, M. W., Guilhot, F., et al. (2020) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 1,547

Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease

Rousselot, P., Charbonnier, A., Cony-Makhoul, P., Agape, P., Nicolini, F. E., Varet, B., Gardembas, M., Etienne, G., Réa, D., Roy, L., et al. (2014) · Journal of Clinical Oncology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 416

Evaluation of residual disease and TKI duration are critical predictive factors for molecular recurrence after stopping imatinib first-line in chronic phase CML patients

Nicolini, F. E., Dulucq, S., Boureau, L., Cony-Makhoul, P., Charbonnier, A., Escoffre-Barbe, M., Rigal-Huguet, F., Coiteux, V., Varet, B., Dubruille, V., et al. (2019) · Clinical Cancer Research

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 111

Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial

Prey, S., Ezzedine, K., Doussau, A., Grandoulier, A.-S., Barcat, D., Chatelus, E., Diot, E., Durant, C., Hachulla, E., de Korwin-Krokowski, J.-D., et al. (2012) · British Journal of Dermatology

Systemic Sclerosis and Related DiseasesConnective tissue disorders research

Cited by 105

Apoptosis and autophagy have opposite roles on imatinib-induced K562 leukemia cell senescence

Drullion, C., Trégoat, C., Lagarde, V, Tan, S., Gioia, R., Priault, M., Djavaheri-Mergny, M., Brisson, A., Auberger, P., Mahon, F.-X., et al. (2012) · Cell Death & Disease

Telomeres, Telomerase, and SenescenceAutophagy in Disease and Therapy

Cited by 88

A single nucleotide polymorphism in cBIM is associated with a slower achievement of major molecular response in chronic myeloid leukaemia treated with imatinib

Augis, V., Airiau, K., Josselin, M., Turcq, B., Mahon, F.-X., & Belloc, F. (2013) · PLoS ONE

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 35

Treatment‐free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5‐year analysis of DASFREE

Shah, N. P., García‐Gutiérrez, V., Jiménez‐Velasco, A., Larson, S. M., Saussele, S., Rea, D., Mahon, F., Levy, M. Y., Gómez‐Casares, M. T., Mauro, M. J., et al. (2023) · British Journal of Haematology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 29

Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment‐free remission period after imatinib discontinuation: Results of the French Nilo post‐ STIM study

Dulucq, S., Rigal‐Huguet, F., Nicolini, F. E., Cony‐Makhoul, P., Escoffre‐Barbe, M., Gardembas, M., Legros, L., Rousselot, P., Liu, J., Rea, D., et al. (2023) · British Journal of Haematology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 22

A genome‐scale CRISPR knock‐out screen in chronic myeloid leukemia identifies novel drug resistance mechanisms along with intrinsic apoptosis and MAPK signaling

Lewis, M., Prouzet‐Mauléon, V., Lichou, F., Richard, E., Iggo, R., Turcq, B., & Mahon, F. (2020) · Cancer Medicine

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 19

Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial

Dulucq, S., Nicolini, F. E., Rea, D., Cony-Makhoul, P., Charbonnier, A., Escoffre-Barbe, M., Coiteux, V., Lenain, P., Rigal-Huguet, F., Liu, J., et al. (2022) · Haematologica

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 17

Effect of tyrosine kinase inhibitors on stemness in normal and chronic myeloid leukemia cells

Charaf, L., Mahon, F.-X., Lamrissi-Garcia, I., Moranvillier, I., Beliveau, F., Cardinaud, B., Dabernat, S., de Verneuil, H., Moreau-Gaudry, F., & Bedel, A. (2017) · Leukemia

Chronic Myeloid Leukemia TreatmentsPluripotent Stem Cells Research

Cited by 16